Skip to main content
SpringerLink
Log in

PET and PET/CT with F-18 Fluoride in Bone Metastases

  • Chapter
PET in Oncology

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 170))

Abstract

Lung cancer is the most common malignant tumor of the male patient [1]. In Germany, 29,000 men died of lung cancer in the year 1995. The mortality rate has decreased slightly in the last few decades to 45 cases per 100,000 inhabitants. For women, lung cancer represents the third most common malignant tumor, increasing steadily over the last few decades. Therefore, the standardized mortality rate has reached a level of 9.6 cases per 100,000 inhabitants per year for the year 1995 [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland 1981–1990. Springer, Berlin New York Heidelberg

    Google Scholar 

  2. Schalhorn A (1985) Bronchialkarzinom: Möglichkeiten und Grenzen der Chemotherapie. Fortschr Med 103:309–311

    PubMed  CAS  Google Scholar 

  3. Schalhorn A (1985) Bronchialkarzinom: Möglichkeiten und Grenzen der Chemotherapie. Fortschr Med 103:453–456

    PubMed  CAS  Google Scholar 

  4. Sobin LH, Wittekind C (1997) TNM classification of malignant tumors, 5th edn. Wiley-Liss, New York

    Google Scholar 

  5. Stahel RA, Ginsberg R, Havemann K et al (1989) Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 5:119–126

    Article  Google Scholar 

  6. Stuschke M, Heilmann HP (1996) Lunge und Mediastinum. In: Scherer E, Sack H (eds) Strahlentherapie. Springer, Berlin New York Heidelberg

    Google Scholar 

  7. Holmes EC (1989) Surgical adjuvant therapy of NSCLC. J Surg Oncol 42 [Suppl l]:26–33

    Google Scholar 

  8. Dosoretz D, Galmarini D, Rubenstein JH et al (1993) Local control in medically inoperable lung cancer: analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiol Oncol Biol Phys 27:507–516

    CAS  Google Scholar 

  9. Noordijk EM, van der Poest, Hermans J, Wever AMJ, Leer JWH (1988) Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. Radiother Oncol 13:83–89

    Article  PubMed  CAS  Google Scholar 

  10. Sandler HM, Curran WJ, Turrisi AT (1990) The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I NSCLC. Int J Radiol Oncol Biol Phys 10:9–13

    Article  Google Scholar 

  11. Bülzebruck H, Danzer B, Hilkemeier G et al (1998) Metastasierung und Prognose des kleinzelligen Bronchialkarzinoms. Onkologe 4:1039–1047

    Article  Google Scholar 

  12. Line D, Deeley TJ (1971) The necropsy findings in carcinoma of the bronchus. Br J Dis Chest 65:238

    PubMed  CAS  Google Scholar 

  13. Wolf M (1998) Kleinzelliges Bronchialkarzinom: Klinische Präsentation, Diagnostik und prognostische Faktoren. Onkologe 4:1005–1018

    Article  Google Scholar 

  14. Hansen HH, Muggia FM (1972) Staging of inoperable patients with bronchogenic carcinoma with special reference to bone marrow and peritoneoscopy. Cancer 30:1395–1401

    Article  PubMed  CAS  Google Scholar 

  15. Schalhorn A, Sunder-Plassmann L (2000) Maligne Tumoren der Thorakal-und Mediastinalorgane. In: Wilmanns W, Huhn D, Wilms K (eds) Internistische Onkologie.Thieme, Stuttgart, pp 617–642

    Google Scholar 

  16. Bonomi PD, Finkelstein DM, Ruckdeschel JC et al (1989) Combination chemotherapy vs. single agents followed by combinations chemotherapy in stage IV NSCLC: a study of the eastern cooperative oncology group. J Clin Oncol 7:1602–1613

    PubMed  CAS  Google Scholar 

  17. Drings P, Becker H, Bül zebruck H, Manke HG, Tessen HW (1990) Chemotherapie des fortgeschrittenen nichtkleinzelligen Bronchialkarzinoms mit Ifosfamid und Etoposid. Tumordiagn Ther 11:79–84

    Google Scholar 

  18. Spiegelman D, Maurer H, Ware JH (1989) Prognostic factors in SCLC: an analysis of 1521 patients. J Clin Oncol 7:344–354

    PubMed  CAS  Google Scholar 

  19. Rosell R, Lopez-Cabrerizo MP, Astudillo J (1997) Pre-operative chemotherapy for stage IIIA NSCLC. Curr Opin Oncol 9:149–155

    Article  PubMed  CAS  Google Scholar 

  20. Albain KS, Crowley JJ, Leblanc M, Livingston RB (1990) Determinants of improved outcome in SCLC: an analysis of the 2580 patients-Southwest Oncology Group data base. J Clin Oncol 8:1563–1574

    PubMed  CAS  Google Scholar 

  21. Manegold C, Bül zebruck H, Drings P, Vogt-Moykopf I (1989) Prognostische Faktoren beim kleinzelligen Bronchialkarzinom. Onkologe 12:240–245

    CAS  Google Scholar 

  22. Golz R, Stör kel S (1999) Anatomie und Pathologie des Prostatakarzinom. In: Hinkelbein W, Miller K, Wiegel T (eds) Prostatakarzinom. Springer, Berlin New York Heidelberg

    Google Scholar 

  23. Statistisches Bundesamt (1994) Gesundtheitswesen. Fachserie 12, Reihe 4 Todesursachen in Deutschland, Wiesbaden

    Google Scholar 

  24. Saitoh H, Hida M, Shimbo T et al (1984) Metastatic patterns of prostatic cancer. Cancer 54:3078–3084

    Article  PubMed  CAS  Google Scholar 

  25. De la Monte SM, Moore GW, Hutchins GM (1986) Metastatic behaviour of prostate cancer. Cancer 58:985–993

    Article  PubMed  Google Scholar 

  26. Ravery V, Schmid HP, Toublanc M, Boccon-Gibod L (1996) Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate cancer? Cancer 78:1079–1084

    Article  PubMed  CAS  Google Scholar 

  27. Badalament RA, Miller MC, Peller PA et al (1996) An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sexant core biopsies with prostate specific antigen level. J Urol 156:1375–1380

    Article  PubMed  CAS  Google Scholar 

  28. Breul J, Binder K, Här tung R (1991) Fehler bei der präoperativen Bestimmung des lokalen Tumorstadiums bei der radikalen Prostatektomie. In: Härtung R, Kropp A (eds) Urologische Beckenchirurgie. Springer, Berlin New York Heidelberg, pp 271–298

    Google Scholar 

  29. Rorvik J, Halvorsen OJ, Servoll E, Haukaas S (1994) Transrectal ultrasonography to assess local extent of prostatic cancer before radical prostatectomy. Br J Urol 73:65–69

    Article  PubMed  CAS  Google Scholar 

  30. Partin A, Yoo J, Carter HB (1990) PSA in the staging of localized prostate cancer: influence of tumor differentiation tumor volume and benign hyperplasia. J Urol 143:747–756

    PubMed  CAS  Google Scholar 

  31. Kleer E, Oesterlin JE (1993) PSA and staging of localized prostate cancer. Urol Clin North Am 20:695–705

    PubMed  CAS  Google Scholar 

  32. Catalona WJ, Smith DS, Ratliff TL Basler JW et al (1991) Measurement of PSA in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161

    PubMed  CAS  Google Scholar 

  33. Wirth MP, Frohmül ler HGW (1992) PSA and prostate acid phosphatase in the detection of early prostate cancer and the prediction of regional lymph node metastases. Eur Urol 22:27–32

    PubMed  CAS  Google Scholar 

  34. Shreve PD, Grossman HB, Gross MD, Wahl RL (1996) Metastatic prostate cancer: initial findings of PET with F-18 fluoro-D-glucose. Radiology 199:751–756

    PubMed  CAS  Google Scholar 

  35. Partin AW, Kattan MW, Subong EN et. al (1997) Combination of PSA, clinical stage, and Gleason Score to predict pathological stage of localized prostate cancer. JAMA 277:1445–1451

    Article  PubMed  CAS  Google Scholar 

  36. Klan R, Meier T, Knispel HH, Wegner HE, Miller K (1995) Laparoscopic pelvic lymphadenectomy in prostatic cancer. Urol Int 55:78–83

    PubMed  CAS  Google Scholar 

  37. Catalona WJ, Smith DJ (1994) 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 152:1837–1842

    PubMed  CAS  Google Scholar 

  38. Ohori M, Goag JR, Wheeler TM et al (1994) Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152:1843–1849

    PubMed  CAS  Google Scholar 

  39. Hanks GE, LeeWR, Haulon MS et al (1996) Conformai technique dose escalation for prostate cancer. Int J RadiatOncol Biol Phys 35:861–868

    CAS  Google Scholar 

  40. Zietman AL, Shipley WU (1993) Randomized trials in loco-regionally confined prostate cancer: past present and future. Semin Radiol Oncol 3:210–220

    Article  Google Scholar 

  41. Epstein JI, Pizov G, Walsh PC (1993) Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71:3586–3589

    Google Scholar 

  42. Perez CA, Hanks GE, Leibel SA et al (1993) Localized carcinoma of the prostate (stages Tl, T2 and T3). Cancer 72:3156–3173

    Article  PubMed  CAS  Google Scholar 

  43. Chybowski FM, Keller JL, Bergstrahl EJ, Oesterling JE (1991) Predicting radionuclide bone scan finding in patients with newly diagnosed untreated prostate cancer. J Urol 145:313–318

    PubMed  CAS  Google Scholar 

  44. Andriole GL, Kavoussi LR, Torrence JR (1988) Transrectal ultrasonography in the diagnosis and staging of the carcinoma of the prostate. J Urol 140:758–760

    PubMed  CAS  Google Scholar 

  45. Noldus J, Stamey TA (1996) Limitations of serum PSA in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. J Urol 155:232–237

    Article  PubMed  CAS  Google Scholar 

  46. Kelsey JL, Gammon MD (1991) The epidemiology of breast cancer. Cancer 41:146–65

    CAS  Google Scholar 

  47. Sondik EJ (1994) Breast cancer trends. Incidence, mortality and survival. Cancer 74:995–999

    Article  PubMed  CAS  Google Scholar 

  48. Possinger K, Große Y (2000) Mammakarzinome und gynäkologische Tumoren. In: Wilmanns W, Huhn D, Wilms K (eds) Internistische Onkologie Thieme, Stuttgart, pp 452–508

    Google Scholar 

  49. Spratt JS, Donegan WL. Cancer of the breast. Saunders Philadelphia 1979.

    Google Scholar 

  50. Tabar I, Grad A, Holmberg LH et al (1985) Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1:829

    Article  PubMed  CAS  Google Scholar 

  51. Boag JW, Jaybittle JL, Fowler JR (1971) The number of patinets required in a clinical trial. Brit J Radiol 44:122

    Article  PubMed  CAS  Google Scholar 

  52. Smart CR, Myers MH, Gloeckler LA (1978) Implications from SEER data on breast cancer management. Cancer 41:787–789

    Article  PubMed  CAS  Google Scholar 

  53. Koscielny SM, Tubiana M, Le MG et al (1984) Breast cancer. Relationship between the size of the primary tumor and the probability of metastatic dissemination. Br J Cancer 49:709

    PubMed  CAS  Google Scholar 

  54. Donegan WL Epidemiology. In: Donegan WL, Spratt JS (eds) Cancer of the breast. Saunders, Philadelphia, pp 39–46

    Google Scholar 

  55. Foster RS Jr, Lang SP, Costanza MC et al (1978) Breast self-examination practices and breast cancer stage. New Engl J Med 299:265–270

    PubMed  Google Scholar 

  56. Andersson I (1988) Mammographie screening and mortality from breast cancer: Malmö mammographie screening trial. BMJ 297 943–948

    Article  PubMed  CAS  Google Scholar 

  57. Frisell J, Eklund G, Hellström L et al (1991) Randomized study of mammography screening-preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat 18:49–56

    Article  PubMed  CAS  Google Scholar 

  58. Miller AB, Baines CJ, To T et al (1992) Canada national breast screening study. Can Med Assoc J 147:1459–1488

    CAS  Google Scholar 

  59. Meuret G (1995) Grundlagen des Mammakarzinoms. In: Meuret G (ed) Mammakarzinom. Thieme, Stuttgart, pp 1–21

    Google Scholar 

  60. Clark GM, Sledge GW, Osborne CK, McGuire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5:55–61

    PubMed  CAS  Google Scholar 

  61. Come SE, Schnipper LE (1991) Myelophtisisanemia and other aspects of bone marrow involvement. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast diseases. Lippincott, Philadelphia, pp 761–766

    Google Scholar 

  62. Perez DJ, Powles TJ, Milan J et al (1983) Detection of breast carcinoma metastases in bone: relative merits of x-rays and skeletal scintigraphy. Lancet 2:613–616

    Article  PubMed  CAS  Google Scholar 

  63. Rossing N, Munck O, Nielsen SP et al (1982) What do early bone scans tell about breast cancer patients? Eur J Cancer Clin Oncol 18:629–636

    Article  PubMed  CAS  Google Scholar 

  64. Kamby C, Bruun Rasmussen B, Kristensen B (1991) Prognostic indicators of metastatic bone disease in human breast cancer. Cancer 68:2045–2050

    Article  PubMed  CAS  Google Scholar 

  65. Muss HB (1992) Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21:15–26

    Article  PubMed  CAS  Google Scholar 

  66. Diel IJ, Solomayer EF, Costa SD et al (1998) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357–363

    Article  PubMed  CAS  Google Scholar 

  67. Conte N, Giannessi PG, Latreille J et al (1994) Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Br J Cancer 70: 554–558

    Google Scholar 

  68. Van Holten-Verzantvoort ATM, Hermans J et al (1996) Does supportive pamodronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients. Eur J Cancer 32:450–454

    Article  Google Scholar 

  69. Aberizk WJ, Silver B, Henderson IC et al (1986) The use of radiotherapy for treatment of isolated locore-gional recurrence of breast carcinoma after mastectomy. Cancer 58:1214–1218

    Article  PubMed  CAS  Google Scholar 

  70. Janjan NA, McNeese MD, Buzdar AU et al (1986) Management of locoregional recurrent breast cancer. Cancer 58:1552–1556

    Article  PubMed  CAS  Google Scholar 

  71. Noguchi S, Miyauchi K, Nishizawa Y et al (1987) Results of surgical treatment for sternal metastases in breast cancer. Cancer 60:2524–2531

    Article  Google Scholar 

  72. Schirrmeister H, Guhlmann A, Kotzerke J et al (1999) Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 17:2381–2389

    PubMed  CAS  Google Scholar 

  73. Gambhir SS, Czernin J, Schwimmer J et al (2001) A tabulated summary of the FDG-PET literature. J Nucl Med 42:1S–93S

    Google Scholar 

  74. Blau M, Nagler W, Bender MA (1962) A new isotope for bone scanning. J Nucl Med 3:332–334

    PubMed  CAS  Google Scholar 

  75. Cook G, Fogelman I (2001) The role of positron emission tomography in skeletal disease. Semin Nucl Med 1:50–61

    Article  Google Scholar 

  76. Hawkins RA, Choi Y, Huang SC et al (1992) Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 33:633–642

    PubMed  CAS  Google Scholar 

  77. Hoh CK, Hawkins RA, Dahlbom M et al (1993) Whole body skeletal imaging with F-18 fluoride ion and PET. J Comp Assist Tomogr 17:34–41

    Article  CAS  Google Scholar 

  78. Me Neil BJ et al (1973) Fluroine-18 bone scintigraphy in children with osteosarcoma or Ewing’s sarcoma. Radiology 109:627–631

    Google Scholar 

  79. Buck AC et al (1975) Serial fluorine-18 bone scans in the follow-up of carcinoma of the prostate. Br J Urol 47:287–294

    Article  PubMed  CAS  Google Scholar 

  80. Rosenfield N, Treves S (1974) Osseous and extraosse-ous uptake of fluorine-18 and techentium-99m poly-phosphate in children with neuroblastoma. Radiology 111:127–133

    PubMed  CAS  Google Scholar 

  81. Schirrmeister H, Rentschier M, Kotzerke J et al (1998) Skeletal imaging with F-18 NaF PET and comparison with planar scintigraphy. Fortschr Röntgenstr 168:451–456

    Article  CAS  Google Scholar 

  82. Schirrmeister H, Guhlmann CA, Diederichs CG, Träger H, Reske SN (1999) Planar bone imaging vs. F-18 PET in patients with cancer of the prostate, thyroid and lung. J Nucl Med 40:1623–1629

    PubMed  CAS  Google Scholar 

  83. Schirrmeister H, Glatting G, Hetzel J, Nussle K, Arslandemir C, Buck AK, Dziuk K, Gabelmann A, Reske SN, Hetzel M (2001) Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42:1800–1804

    PubMed  CAS  Google Scholar 

  84. Palmedo H, Schaible R, Textor J, Ko Y, Grohe C, von Mallek D, Ezziddin S, Reinhardt MJ, Biersack H J (2002) PET with 18F Fluoride compared to bone scintigraphy in the diagnosis of bone metastases: results of a prospective study. J Nucl Med [Suppl]:1150–1151

    Google Scholar 

  85. Lonneux M, Borbath II, Berliere M, Kirkove C, Pauwels S (2000) The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3:45–49

    Article  PubMed  Google Scholar 

  86. Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, Nasu S, Suzuki Y, Yasuda S, Shohtsu A (2001) Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy. Nucl Med Commun 22:875–879

    Article  PubMed  CAS  Google Scholar 

  87. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC (2002) Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylène diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128:325–328

    Article  PubMed  CAS  Google Scholar 

  88. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, Herndon JE, Patz EF Jr (1999) Staging non-small cell lung cancer with whole-body PET. Radiology 212:803–809

    PubMed  CAS  Google Scholar 

  89. Garcia JR, Simo M, Perez G, Soler M, Lopez S, Setoain X, Lomena F (2003) 99mTc-MDP bone scintigraphy and 18F-FDG positron emission tomography in lung and prostate cancer patients: different affinity between lytic and sclerotic bone metastases. Eur J Nucl Med Mol Imaging 30:1714.

    Article  PubMed  CAS  Google Scholar 

  90. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287–297

    PubMed  Google Scholar 

  91. Buscombe JR, Holloway B, Roche N, Bombardieri E (2004) Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging 48:109–118

    PubMed  CAS  Google Scholar 

  92. Ghanem N, Altehoefer C, Kelly T, Lohrmann C, Winterer J, Schäfer O, Bley TA, Moser E, Langer M (2006) Whole-body MRI in comparison to skeletal scintigraphy in detection of skeletal metastases in patients with solid tumors. In Vivo 20:173–182

    CAS  Google Scholar 

  93. Frat A, Agildere M, Gencoglu A, Cakir B, Akin O, Akcali Z, Aktas A (2006) Value of whole-body turbo short tau inversion recovery magnetic resonance imaging with panoramic table for detecting bone metastases: comparison with 99MTc-methylene diphosphonate scintigraphy. J Comput Assist Tomogr 30:151–156

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Nuklearmedizin des Universitätsklinikums Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany

    Prof. Dr. med. H. Palmedo & Prof. Dr. med. Y. Ko

  2. Medizinische Klinik II des Universitätsklinikums Bonn, Sigmund-Freud-Straße 25, 53127, Bonn, Germany

    Prof. Dr. med. C. Grohé & PD Dr. med. S. Tasci

Authors
  1. Prof. Dr. med. H. Palmedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. C. Grohé
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Y. Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. PD Dr. med. S. Tasci
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Nuklearmedizin, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany

    Stefan Dresel

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Palmedo, H., Grohé, C., Ko, Y., Tasci, S. (2008). PET and PET/CT with F-18 Fluoride in Bone Metastases. In: Dresel, S. (eds) PET in Oncology. Recent Results in Cancer Research, vol 170. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-31203-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-31203-1_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31202-4

  • Online ISBN: 978-3-540-31203-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation